Clinical trial

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg…

NCT00059657 · Tanabe Pharma Corporation, Industry · Completed

Key facts

NCT number NCT00059657
Title Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
Official title A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM in Conjunction With Peripheral Revascularization for the Treatment of Critical Leg Ischemia
Lead sponsor Tanabe Pharma Corporation, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Peripheral Vascular Disease
Intervention type Drug
Interventions Ecraprost in lipid emulsion
Enrollment 280
Start date Aug 1, 2001
Completion Nov 1, 2005
First posted May 2, 2003
Last update posted May 19, 2006
Countries United Kingdom, United States

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies